Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Resmed Inc
(NY:
RMD
)
207.17
-6.09 (-2.86%)
Official Closing Price
Updated: 7:00 PM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Resmed Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
August 12, 2022
Via
Benzinga
Earnings Scheduled For August 11, 2022
August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $3,400 Today
August 03, 2022
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 11.43% on an annualized basis producing an average annual return of 19.33%. Currently, ResMed has a market capitalization of...
Via
Benzinga
Analyst Ratings for ResMed
June 06, 2022
Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:
Via
Benzinga
ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract
April 29, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About ResMed
April 06, 2022
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
How Is The Market Feeling About ResMed?
July 25, 2022
ResMed's (NYSE:RMD) short percent of float has fallen 6.8% since its last report. The company recently reported that it has 1.39 million shares sold short, which is 0.96% of all...
Via
Benzinga
Semiconductor Shortages - See How ResMed Is Tackling
July 22, 2022
ResMed Inc (NYSE: RMD) has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips.
Via
Benzinga
Here's How Much $1000 Invested In ResMed 10 Years Ago Would Be Worth Today
July 18, 2022
ResMed (NYSE:RMD) has outperformed the market over the past 10 years by 10.69% on an annualized basis producing an average annual return of 21.91%. Currently, ResMed has a market capitalization of...
Via
Benzinga
Peering Into ResMed's Recent Short Interest
July 08, 2022
ResMed's (NYSE:RMD) short percent of float has risen 14.44% since its last report. The company recently reported that it has 1.50 million shares sold short, which is 1.03% of all...
Via
Benzinga
7 Growth Stocks to Buy in July 2022
July 04, 2022
The severe macroeconomic climate has led investors toward defensive plays, creating buy opportunities in the following growth stocks.
Via
InvestorPlace
Analyzing ResMed's Short Interest
June 22, 2022
ResMed's (NYSE:RMD) short percent of float has risen 5.62% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 0.94% of all...
Via
Benzinga
Expert Ratings For ResMed
January 31, 2022
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
June 15, 2022
ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 9.9% on an annualized basis producing an average annual return of 16.19%. Currently, ResMed has a market capitalization of $29.81...
Via
Benzinga
ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How
June 14, 2022
Via
Benzinga
10 Biggest Price Target Changes For Monday
June 06, 2022
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.
Via
Benzinga
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
June 06, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq tumbled over 300 points in the previous session despite better-than-expected jobs report for May.
Via
Benzinga
If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today
June 02, 2022
ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of...
Via
Benzinga
ResMed Earnings Perspective: Return On Invested Capital
May 03, 2022
Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters.
Via
Benzinga
What 3 Analyst Ratings Have To Say About ResMed
April 29, 2022
Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...
Via
Benzinga
Earnings Outlook For ResMed
April 27, 2022
ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an...
Via
Benzinga
Ten Healthcare Companies With High Payout Ratio
March 25, 2022
The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low.
Via
Talk Markets
3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives
March 23, 2022
Energy and commodity plays were top performers Wednesday.
Via
Investor's Business Daily
Markets Fall Amid Rising Oil Prices
March 23, 2022
U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Oil prices have also...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
February 25, 2022
The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions.
Via
InvestorPlace
Ominous Death Cross Forms On ResMed's Chart
February 02, 2022
If history is any guide, there may be trouble ahead for shares of ResMed (NYSE:RMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
ResMed's Return on Invested Capital Overview
January 28, 2022
According to Benzinga Pro, during Q2, ResMed (NYSE:RMD) earned $201.75 million, a 0.91% increase from the preceding quarter. ResMed's sales decreased to $894.87 million, a 1.01%...
Via
Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
January 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall
January 28, 2022
ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.